Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Subscribe To Our Newsletter & Stay Updated
